{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-014806","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.782067+00:00","generated_at":"2026-05-17T10:41:14.833020+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M","bullets":["FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.","Phase 2 SKNJCT-003 randomized >75% of 90 participants; interim analysis showed >60% clinical clearance.","Cash $9.7M at Q2-end, up from $4.0M Q1; raised $11.5M net from financings and warrant exercises.","Q2 net loss $6.2M vs $3.6M YoY; operating expenses $6.0M vs $3.6M YoY.","CFO James Quinlan exercised 145,000 stock options for ~$156,250 in proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-014806","json":"https://secwatch.observer/filing/0001062993-25-014806.json","markdown":"https://secwatch.observer/filing/0001062993-25-014806.md","text":"https://secwatch.observer/filing/0001062993-25-014806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/0001062993-25-014806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:41:14.833020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}